Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, is excited to announce its latest patient group partnerships.
Healx
Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments.
Address :
Charter house 66-68 Hills Road Cambridge
Post Code: CB2 1LA
Country: United Kingdom
Website: https://healx.io/
Membership Type: Corporate 51+
Healx's AI drug discovery platform leverages public and proprietary biomedical data and features the world’s leading knowledge graph for rare diseases. Combining their technology with patient insights and drug discovery expertise, Healx’s mission is to advance 100 rare disease treatments towards the clinic by 2025.
There are no Products & Services to display
09-04-2021
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, announced that it would be collaborating with the PKD Charity to identify and progress novel treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Autosomal Recessive Polycystic Kidney Disease (ARPKD).
09-03-2021
In Healx's latest blog, Co-Founder and CEO, Tim Guilliams shares his top tips for not just growing but retaining an all-star team this year.
14-01-2021
Mission: Cure is a coalition of patients, doctors, researchers and entrepreneurs who are committed to advancing new therapies and cures for currently untreatable diseases. Their primary focus is on chronic pancreatitis, a rare inflammatory condition that affects over a million people across the globe. A new partnership will combine Healx’s AI and drug discovery expertise with Mission: Cure’s...
13-01-2021
In the first of Healx's new blog series, Senior Director of People, Leigh-Anne Jansen van Rensburg, explores the ways in which Healx has adapted its onboarding processes to offer a fully digital experience to new starters and help them build important connections when working remotely.
07-12-2020
Healx, the AI-powered, patient-inspired technology company specialising in treatments for rare diseases, has today opened applications to v.2.0 of its Rare Treatment Accelerator. Building on the success of their v.1.0 call last year, which was focused on patient group partnerships, Healx is now looking to build a global network of academic groups, patient groups and early-stage biotechs to...
17-11-2020
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, is proud to announce its partnership with the Foundation for Angelman Syndrome Therapeutics (FAST) today. This partnership will focus on developing therapies for Angelman syndrome, a rare neurogenetic disorder that affects approximately one in 15,000 people...
12-08-2020
Healx, the AI-powered, patient-inspired technology company accelerating the discovery and development of rare disease treatments at scale, today announced its Rare Treatment Accelerator Programme (RTA) partnership with Muscular Dystrophy UK (MDUK).
16-07-2020
Experienced tech leader Meri Williams joins Healx - the AI-powered, patient-inspired technology company - from challenger bank Monzo, as Chief Technology Officer.
17-06-2020
Healx, the AI-powered and patient-inspired tech company specialising in accelerating the discovery and development of rare disease treatments, today announced a partnership with US and Europe-based patient group Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF).
15-04-2020
Healx, the AI-powered, patient-inspired biotech specialising in rare diseases, today announces it is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure...
06-04-2020
Healx, the AI-powered and patient-inspired technology company specialising in finding new treatments for rare diseases, today announced the appointment of Dr Anthony Hall, MB BS BSc, as Chief Medical Officer (CMO).
04-02-2020
Healx, the AI-powered biotechnology company focused on developing breakthrough treatments for rare diseases, today announces it has entered into an agreement with Boehringer Ingelheim to identify indications related to rare neurological diseases.
09-12-2019
Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that applications are now being accepted for its Rare Treatment Accelerator (RTA).
21-11-2019
Healx is delighted to announce that its Head of Business Development, Michale Bouskila-Chubb has been featured in the sixth annual Movers and Shakers in BioBusiness report which showcases the 50 trailblazers shaping the future of the UK life sciences sector.
06-11-2019
Healx, the AI-powered and patient-inspired technology company specialising in treatments for rare diseases, today announces that it has raised $56 million in a Series B financing round, led by one of Europe’s largest VC firms Atomico and joined by Intel Capital, Global Brain and btov Partners.
16-10-2019
Healx has announced a collaboration with scientists at The Institute of Cancer Research, London (ICR) to discover new possible ways of treating diffuse intrinsic pontine glioma (DIPG), a life-limiting childhood brain cancer for which no treatments currently exist.
08-10-2019
Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, is pleased to announce the appointment of Neil Thompson, PhD, as Chief Scientific Officer (CSO).
11-07-2019
Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced the appointment of Kate Hilyard PhD as Chief Operating Officer (COO).
03-10-2018
Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, has announced a $10 million Series A funding round, led by Balderton Capital, Europe’s leading early-stage venture investor. Existing investors, Jonathan Milner and Amadeus Capital Partners also participated in the round.
26-07-2018
There are no events to display
There are no jobs to display
No Blog articles found
